Colchicine is a kind of natural alkaloid used primarily for the treatment and prevention of gout attack and familial mediterranean fever (FMF) in the past. However, its application in gout management has declined significantly in recent years due to its considerable toxicity and the emergence of novel anti-gout therapeutic agents. In contrast, the clinical application of colchicine in other immunological and anti-inflammatory diseases is increasing. Especially after the U.S. FDA approved colchicine as a protective treatment for cardiovascular disease in 2023, this old drug has regained the attention and attention of researchers. This article searches the literature reports, diagnostic and therapeutic guidelines related to colchicine in recent years, summarized the progress of clinical research in the treatment of gout, cardiovascular disease, novel coronavirus pneumonia, dermatological diseases and other diseases and the adverse reactions about colchicine, in order to provide references for better application of colchicine in clinic.

1.崔光芬, 杜文文, 金鹏程, 等. 秋水仙碱提取分离研究进展 [J]. 江苏农业学报, 2023(1): 295-304. [Cui GF, Du WW, Jin  PC, et al. Advances in extraction and separation of colchicine[J]. Jiangsu Journal of Agricultural Sciences, 2023(1): 295-304.] DOI: 10.3969/j.issn.1000-4440.2023.01.033.

2.汪嫒嫒, 曹欣洋, 田倩倩, 等. 索氏提取法-高效液相色谱法测定卷丹百合中秋水仙碱的含量[J]. 中南农业科技, 2024, 45(9): 36-40. [Wang AA, Cao XY, Tian QQ, et al. Determination of narcissus line in lily of platyphyllum by soxhlet extraction and high performance liquid chromatography[J]. South-Central Agricultural Science and Technology, 2019, 45(9): 36-40.] DOI: 10.3969/j.issn.1007-273X.2024.09.008.

3.Slobodnick A, Shah B, et al. Update on colchicine, 2017[J]. Rheumatology (Oxford), 2018, 57(suppl_1): i4-i11. DOI: 10.1093/rheumatology/kex453.

4.Leung YY, Yao Hui LL, Kraus VB. Colchicine update on mechanisms of action and therapeutic uses[J]. Semin Arthritis Rheum, 2015, 45(3): 341-350. DOI: 10.1016/j.semarthrit.2015.06.013.

5.Lunzer R, Delle-Karth G, Zeitlinger M, et al. Colchicine-phoenix from the ashes[J]. Wien Klin Wochenschr, 2025, 137(Suppl 1): 1-33. DOI: 10.1007/s00508-024-02490-7.

6.王明珠, 周阳, 何凯桐, 等. Hippo通路在肿瘤发生发展中作用机制的研究进展[J]. 现代肿瘤医学, 2022, 30(16): 3061-3064. [Wang MZ, Zhou Y, He KT, et al. Research progress on the mechanism of hippo pathway in tumorigenesis anddevelopment[J]. Journal of Modern Oncology, 2022, 30(16): 3061-3064.] DOI: 10.3969/j.issn.1672-4992.2022.16.040.

7.徐燕燕, 朱乐乐, 李苗苗, 等. 秋水仙碱经由Hippo信号通路对小鼠肝癌的影响及其机制研究[J]. 安徽医科大学学报, 2024, 59(2): 185-192. [Xu YY, Zhu LL, Li MM, et al. Effects of colchicinevia Hippo signaling pathway on mouse liver cancer and its mechanism research[J]. Acta Universitatis Medicinalis Anhui, 2024, 59(2): 185-192.] DOI: 10.19405/j.cnki.issn1000-1492.2024.02.001.

8.王昱, 邓雪蓉, 张卓莉. 2020年美国风湿病学会痛风治疗指南[J] . 中华风湿病学杂志, 2020, 24(12) : 862-864. [Wang  Y, Deng XR, Zhang ZL. 2020 American Society of Rheumatology Gout Treatment Guidelines[J]. Chinese Journal of Rheumatology, 2020, 24(12): 862-864.] DOI: 10.3760/cma.j.c141217-20200612-00251.

9.杨雯雯, 孙永强. 不同剂量秋水仙碱对痛风急性发作的临床疗效[J]. 深圳中西医结合杂志, 2018, 28(8): 113-114. [Yang  WW, Sun YQ. Clinical effect of colchicine at different doses on acute attack of gout[J]. Shenzhen Journal of Integrated Traditional Chinese and Western Medicine, 2018, 28(8): 113-114.] DOI: 10.16458/j.cnki.1007-0893.2018.08.056.

10.张娟娟, 李红, 茅伟安, 等. 中西医药物治疗痛风及高尿酸血症研究进展[J]. 世界临床药物, 2024, 45(6): 665-672. [Zhang JJ, Li H, Mao WA, et al. Progress in the medication of gout and hyperuricemia with Chinese and western medicine[J]. World Clinical Drugs, 2024, 45(6): 665-672.] DOI: 10.13683/j.wph.2024.06.016.

11.张积萍. 清热利湿泄浊汤联合秋水仙碱治疗急性痛风性关节炎湿热痹阻证的效果及对炎症反应和血液流变学的影响[J]. 中外医学研究, 2023, 21(22): 63-67. [Zhang JP. Effect of qingre Lishi Xiezhuo decoction combined with colchicine in the treatment of acute gouty arthritis with damp-heat obstruction syndrome and its influence on inflammatory response and hemorheology[J]. Chinese and Foreign Medical Research, 2023, 21(22): 63-67.] DOI: 10.14033/j.cnki.cfmr.2023.22.016.

12.宋伟, 黄玉兰, 曾丽红, 等. 清热止痛液定向透药联合秋水仙碱治疗急性痛风性关节炎临床研究[J]. 医药前沿, 2024, 14(14): 125-127. [Song W, Huang YL, Zeng LH, et al. Clinical study of Qingrezhitong decoction combined with colchicine in the treatment of acute gouty arthritis[J]. Frontiers in Medicine, 2017, 14(14): 125-127.] DOI: 10.3969/j.issn.2095-1752.2024.14.038.

13.樊一桦, 刘维, 文心妍, 等. 加味四妙散联合秋水仙碱治疗急性痛风性关节炎有效性与安全性Meta分析[J]. 天津中医药大学学报, 2022, 41(5): 602-611. [Fan YH, Liu W, Wen XY, et al. Efficacy and safety of Jiawei Simiao powder combined with colchicine for acute gouty arthritis: a Meta-analysis[J]. Journal of Tianjin University of Traditional Chinese Medicine, 2022, 41(5): 602-611.] DOI: 10.11656/j.issn.1673-9043.2022.05.13.

14.Georgin-Lavialle S, Savey L, Cuisset L, et al. French protocol for the diagnosis and management of familial mediterranean fever[J]. Rev Med Interne, 2023, 44(11): 602-616. DOI: 10.1016/J.REVMED.2023.10.441.

15.Romano M, Piskin D, Cinar OK, et al. Familial mediterranean fever; recent advances, future prospectives[J]. Diagnostics (Basel), 2025, 15(7): 813. DOI: 10.3390/diagnostics15070813.

16.Trube J, Sabina M, Khanani A, et al. Colchicine therapy in cardiovascular medicine: a literature reviewt[J]. Am Heart J Plus, 2025, 52: 100525. DOI: 10.1016/J.AHJO.2025.100525.

17.周桐羽, 田蜜, 王中素, 等. 秋水仙碱在冠心病患者治疗中的应用价值[J]. 心血管病学进展, 2025, 46(3): 220-224. [Zhou  TY, Tian M, Wang ZS, et al. Therapeutic value of colchicine in treatment of patients with coronary heart disease[J]. Advances in Cardiovascular Diseases, 2025, 46(3): 220-224.] DOI: 10.16806/j.cnki.issn.1004-3934.2025.03.007.

18.郑刚. 秋水仙碱在心血管病防治中的地位和临床意义[J]. 中华老年心脑血管病杂志, 2022, 24(2): 216-218. [Zheng G. The status and clinical significance of colchicine in the prevention and treatment of cardiovascular diseases[J]. Chinese Journal of Geriatric Heart Brain and Vessel Diseases, 2022, 24(2): 216-218.] DOI: 10.3969/j.issn.1009-0126.2022.02.028.

19.屈炯. 秋水仙碱辅助治疗对不稳定型心绞痛患者心功能、炎性因子和远期预后的影响[J]. 医学理论与实践, 2023, 36(6): 944-946. [Qu J. Effect of adjunctive colchicine therapy on cardiac function, inflammatory factors and long-term prognosis in patients with unstable angina pectoris[J]. The Journal of Medical Theory and Practice, 2023, 36(6): 944-946.] DOI: 10.19381/j.issn.1001-7585.2023.06.014.

20.Aimo A, Pascual-Figal DA, Barison A, et al. Colchicine for the treatment of coronary artery disease[J]. Trends Cardiovasc Med, 2021, 31(8): 497-504. DOI: 10.1016/j.tcm.2020.10.007.

21.Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction[J]. N Engl J Med, 2019, 381(26): 2497-2505. DOI: 10.1056/NEJMoa1912388.

22.王学思, 彭晓东, 李玉昆, 等. 秋水仙碱治疗心血管疾病的研究进展[J]. 中国医药, 2022, 17(9): 1423-1427. [Wang XS, Peng XD, Li YK, et al. Research progress on colchicine in treating cardiovascular diseases[J]. China Medicine, 2022, 17(9): 1423-1427.] DOI: 10.3760/j.issn.1673-4777.2022.09.033.

23.LODOCO (colchicine) tablets[ED/OL]. (2023-06) [2025-01-15] https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215727s000lbl.pdf.

24.陈宏涛. 小剂量秋水仙碱对急性脑梗死患者的疗效及炎症因子水平的影响[J]. 中国合理用药探索, 2022, 19(1): 68-72. [Chen HT. Effect of low-dose colchicine on curative effect and inflammatory factor level in patients with acute cerebral infarction[J]. China Licensed Pharmacist, 2022, 19(1): 68-72.] DOI: 10.3969/j.issn.2022.01.011.

25.Sharaf S, Ashmawy R, Saleh E, et al. Oxygen saturation in hospitalized COVID-19 patients and its relation to colchicine treatment: a retrospective cohort study with an updated systematic review[J]. Medicina (Kaunas), 2023, 59(5): 934. DOI: 10.3390/medicina59050934.

26.Elshiwy K, Amin GEE, Farres MN, et al. The role of colchicine in the management of COVID-19: a Meta-analysis[J]. BMC Pulm Med, 2024, 24(1): 190. DOI: 10.1186/s12890-024-03001-0.

27.Adişen E, Tekin O, Gülekon A, et al. A retrospective analysis of treatment responses of palmoplantar psoriasis in 114 patients[J]. J Eur Acad Dermatol Venereol, 2009, 23(7): 814-819. DOI: 10.1111/j.1468-3083.2009.03197.x.

28.金广连. 秋水仙碱治疗掌跖脓疱病20例疗效观察[J]. 中华全科医师杂志, 2015, 14(11): 885-886. [Jin GL. Efficacy of colchicine in the treatment of palmoplantar pustulosis in 20 cases[J]. Chinese Journal of General Practitioners, 2015, 14(11): 885-886.] DOI: 10.3760/cma.j.issn.1671-7368.2015.11.022.

29.张丽, 陈启红, 丁小珍, 等. 秋水仙碱联合窄谱中波紫外线治疗掌跖脓疱病的临床研究[J]. 基因组学与应用生物学, 2017, 36(4): 1343-1347. [Zhang L, Chen QH, Ding XZ, et al. Clinical observation of colchicine combined with NB-UVB in the treatment of palmoplantar pustulosis[J]. Genomics and Applied Biology, 2017, 36(4): 1343-1347.] DOI: 10.13417/j.gab.036.001343.

30.Dastoli S, Nisticò SP, Morrone P, et al. Colchicine in managing skin conditions: a systematic review[J]. Pharmaceutics, 2022, 14(2): 294. DOI: 10.3390/pharmaceutics14020294.

31.Yurdakul S, Mat C, Tüzün Y, et al. A double-blind trial of colchicine in Behçet's syndrome[J]. Arthritis Rheum, 2001, 44(11): 2686-2692. DOI: 10.1002/1529-0131(200111)44:11<2686::aid-art448>3.0.co;2-h.

32.Davatchi F, Abdollahi BS, Banihashemi AT, et al. Colchicine versus placebo in Behçet's disease: randomized, double-blind, controlled crossover trial[J]. Mod Rheumatol, 2009, 19(5): 542-549. DOI: 10.1007/s10165-009-0200-2.

33.倪志英. 秋水仙碱治疗白塞病疗效分析[J]. 中国卫生标准管理, 2015, 6(6): 247-248. [Ni ZY. Analysis of curative effect of colchicine treatment of Behcet's disease[J]. China Health Standard Management, 2015, 6(6): 247-248.] DOI: 10.3969/j.issn.1674-9316.2015.06.212.

34.许丽云. 秋水仙碱治疗儿童IgA血管炎皮肤病变的疗效观察[D]. 长沙: 中南大学, 2022. DOI: 10.27661/d.cnki.gzhnu. 2022.002806.

35.Gürcan HM, Ahmed AR. Current concepts in the treatment of epidermolysis bullosa acquisita[J]. Expert Opin Pharmacother, 2011, 12(8): 1259-1268. DOI: 10.1517/14656566.2011.549127.

36.Pho LN, Eliason MJ, Regruto M, et al. Treatment of chronic urticaria with colchicine[J]. J Drugs Dermatol, 2011, 10(12): 1423-1428. DOI: 10.1111/j.1610-0387.2011.07819.x.

37.Nabavizadeh SH, Babaeian M, Esmaeilzadeh H, et al. Efficacy of the colchicine add-on therapy in patients with autoimmune chronic urticaria[J]. Dermatol Ther, 2021, 34(6): e15119. DOI: 10.1111/dth.15119.

38.Armyra K, Kouris A, Markantoni V, et al. Hidradenitis suppurativa treated with tetracycline in combination with colchicine: a prospective series of 20 patients[J]. Int J Dermatol, 2017, 56(3): 346-350. DOI: 10.1111/ijd.13428.

39.van der Zee HH, Prens EP. The anti-inflammatory drug colchicine lacks efficacy in hidradenitis suppurativa[J]. Dermatology, 2011, 223(2): 169-173. DOI: 10.1159/000332846.

40.谢意杰, 陈广雄, 王迎林, 等. 秋水仙碱联合小剂量泼尼松治疗结节性红斑的疗效观察[J]. 临床皮肤科杂志, 2015, 44(3): 189-190. [Xie YJ, Chen GX, Wang YL, et al. Efficacy of colchicine combined with low-dose prednisone in the treatment of erythema nodosum[J]. Journal of Clinical Dermatology, 2015, 44(3): 189-190.] DOI: 10.16761/j.cnki.1000-4963.2015.03.004.

41.赵婷婷, 高红霞, 黄海荣, 等. 秋水仙碱联合治疗伴有下肢结节性红斑的肉芽肿性乳腺炎的临床观察[J]. 医学食疗与健康, 2020, 18(21): 89, 91. [Zhao TT, Gao HX, Hang HR, et al. Clinical observtion of Colchicine combined with granulomatous mastitis with erythema nodosum of lower limbs[J]. Medical Diet and Health, 2020, 18(21): 89, 91.] DOI: CNKI:SUN:YXSL.0.2020-21-060.

42.Hrin ML, Patel PV, Jorizzo JL, et al. Colchicine for erythema nodosum: a retrospective case series[J]. J Cutan Med Surg, 2023, 27(6): 662-663. DOI: 10.1177/12034754231204861.

43.Sadjadi SJ, Moshir M. Treatment of acne vulgaris with colchicine[J]. Acta Derm Venereol, 1998, 78(5): 388. DOI: 10.1080/000155598443196.

44.Durdu M, Tehçi T, Karadag AS. Dramatic response to colchicine treatment in acne fulminans patients with cytological hemophagocytosis: a case series of 12 patients[J]. Dermatol Ther, 2022, 35(11): e15856. DOI: 10.1111/dth.15856.

45.Grimaître M, Etienne A, Fathi M, et al. Topical colchicine therapy for actinic keratoses[J]. Dermatology, 2000, 200(4): 346-348. DOI: 10.1159/000018407.

46.Faghihi G, Elahipoor A, Iraji F, et al. Topical colchicine gel versus dicolfenac sodium gel for the treatment of actinic keratoses: a randomized, double-blind study[J]. Adv Med, 2016, 2016: 5918393. DOI: 10.1155/2016/5918393.

47.Altinor S, Oztürkcan S, Hah MM. The effects of colchicine on neutrophil function in subjects with recurrent aphthous stomatitis[J]. J Eur Acad Dermatol Venereol, 2003, 17(4): 469-470. DOI: 10.1046/j.1468-3083.2003.00614_1.x.

48.Pakfetrat A, Mansourian A, Momen-Heravi F, et al. Comparison of colchicine versus prednisolone in recurrent aphthous stomatitis: a double-blind randomized clinical trial[J]. Clin Invest Med, 2010, 33(3): E189-E195. DOI: 10.25011/cim.v33i3.13725.

49.高霞, 程俊雄, 曹文富. 益气法制剂对肝纤维化大鼠的治疗作用及其分子机制[J]. 第三军医大学学报, 2021, 43(8): 692-699. [Gao X, Cheng JX, Cao WF. Efficacy and molecular mechanism of Qi-Tonifying preparations in rats with liver fibrosis[J]. Journal of Army Medical University, 2021, 43(8): 692-699.] DOI: 10.16016/j.1000-5404.202010046.

50.Kershenobich D, Uribe M, Suárez GI, et al. Treatment of cirrhosis with colchicine. a double-blind randomized trial[J]. Gastroenterology, 1979, 77(3): 532-536. DOI: 10.1016/0016-5085(79)90018-0.

51.孔维涵, 方步武, 朱争艳, 等. 秋水仙碱体外抗乙型肝炎病毒的作用[J]. 中国医院药学杂志, 2012, 32(24): 1947-1951. [Kong  WH, Fang BW, Zhu ZY, et al. The inhibitory effects of colchicine on anti-hepatitis B virus in vitro[J]. Chinese Journal of Hospital Pharmacy, 2012, 32(24): 1947-1951.] DOI: 10.13286/j.cnki.chinhosppharmacyj.2012.24.026.

52.Kaplan MM, Bonder A, Ruthazer R, et al. Methotrexate in patients with primary biliary cirrhosis who respond incompletely to treatment with ursodeoxycholic acid[J]. Dig Dis Sci, 2010, 55(11): 3207-3217. DOI: 10.1007/s10620-010-1291-5.

53.梁瑞峰, 宋献美, 葛文静, 等. 大黄素甲醚通过调控Keap1/Nrf2信号通路抗大鼠肝纤维化的作用[J]. 中药药理与临床, 2024, 40(10): 46-51. [Liang RF, Song XM, Ge WJ, et al. Effect of physcion on hepatic fibrosis in rats via regulating Keap1/Nrf2 signaling pathway[J]. Pharmacology and Clinics of Chinese Materia Medica, 2024, 40(10): 46-51.] DOI: 10.13412/j.cnki.zyyl.20240425.007.

54.韦秋琴, 张祖隆. 秋水仙碱抗炎、抗纤维化及抗肿瘤的研究进展[J]. 中国现代医学杂志, 2020, 30(4): 76-81.[Wei QQ, Zhang ZL. Research progress of colchicine in anti-inflammatory, anti-fibrosis and anti-cancer[J]. China Journal of Modern Medicine, 2020, 30(4): 76-81.] DOI: 10.3969/j.issn.1005-8982.2020.04.014.

55.刘春甦. 秋水仙碱治愈慢性重型肝炎伴原发性肝癌1例 [J]. 现代中西医结合杂志, 2002, 11(2): 158. [Liu CS. A case of chronic severe hepatitis with primary liver cancer cured by colchicine[J]. Modern Journal of Integrated Traditional Chinese and Western Medicine, 2002, 11(2): 158.] DOI: 10.3969/j.issn.1008-8849.2002.02.053.

56.Lin ZY, Wu CC, Chuang YH, et al. Anti-cancer mechanisms of clinically acceptable colchicine concentrations on hepatocellular carcinoma[J]. Life Sci, 2013, 93(8): 323-328. DOI: 10.1016/j.lfs.2013.07.002.

57.Bulhões FV, Assis GE, Cazé AB, et al. The action of Colchicine in patients with metabolic syndrome and obesity: perspectives and challenges[J]. Metabolites, 2024, 14(11): 629. DOI: 10.3390/metabo14110629.

58.李荣凌, 周本宏. 秋水仙碱中毒死亡及致急性冠脉综合征与中毒性心肌炎1例[J]. 中国医院药学杂志, 2021, 41(4): 434-436. [Li RL, Zhou BH. Fatality, acute coronary syndrome and toxic myocarditis caused by colchicine poisoning:one case report[J]. Chinese Journal of Hospital Pharmacy, 2021, 41(4): 434-436.] DOI: 10.13286/j.1001-5213.2021.04.20.

59.Montiel V, Huberlant V, Vincent HF, et al. Multiple organ failure after an overdose of less than 0.4 mg/kg of colchicine: role of coingestants and drugs during intensive care management[J]. Clin Toxicol (Phila), 2010, 48(8): 845-848. DOI: 10.3109/15563650.2010.509101.

60.李德友. 抗痛风药非布司他、苯溴马隆及秋水仙碱不良反应分析[J]. 北方药学, 2023, 20(3): 120-122, 125. [Li DY. Analysis of adverse reactions to the antigout drugs febuxostat, benzbromarone, and colchicine[J]. Journal of North Pharmacy, 2023, 20(3): 120-122, 125.] DOI: 10.3969/j.issn.1672-8351.2023.03.040.

61.杨媛, 李静, 甄健存, 等. 抗痛风药别嘌呤醇、苯溴马隆及秋水仙碱不良反应报告分析[J]. 中国医院药学杂志,2013, 33(15): 1296-1297. [Yang Y, Li J, Zhen JC, et al. Analysis of adverse reaction reports of antigout drugs allopurinol, benzbromarone and colchicine[J]. Chinese Journal of Hospital Pharmacy, 2013, 33(15): 1296-1297.] DOI: CNKI:SUN:ZGYZ.0.2013-15-029.

62.周桂庭, 唐娜, 陈楚瑶, 等. 秋水仙碱导致全血细胞减少1例及相关文献分析[J]. 中国合理用药探索, 2021, 18(10): 23-26. [Zhou GT, Tang N, Chen CY, et al. Colchicine induced pancytopenia in one case and related literature analysis[J]. China Licensed Pharmacist, 2021, 18(10): 23-26.] DOI: 10.3969/j.issn.2096-3327.2021.10.006.

63.邱伟伟, 刘德城, 龚碧娇. 秋水仙碱致粒细胞、血小板缺乏1例[J]. 临床合理用药杂志, 2020, 13(22): 104. [Qiu WW, Liu  DC, Gong BJ. A case of granulocyte and platelet deficiency caused by colchicine[J]. Chinese Journal of Clinical Rational Drug Use, 2020, 13(22): 104.] DOI: 10.15887/j.cnki.13-1389/r.2020.22.047.

64.杜忠彩, 刘玉, 周欣蓓, 等. 秋水仙碱中毒患者30例临床荟萃分析[J]. 临床荟萃, 2020, 35(4): 362-365. [Du ZC, Liu  Y, Zhou XP, et al. A Meta-analysis of 30 cases of colchicine poisoning[J]. Clinical Focus, 2020, 35(4): 362-365.] DOI: 10.3969/j.issn.1004-583X.2020.04.016.

65.杜莹珏, 刘维超, 陈茜, 等. 秋水仙碱致慢性肾脏病患者肌肉病变1例[J]. 北京大学学报（医学版）, 2021, 53(6): 1188-1190. [Du YY, Liu WC, Chen Q, et al. A case report of colchicine-ind uced myopathy in a patient with chronic kidney disease[J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1188-1190.] DOI: 10.19723/j.issn.1671-167X.2021.06.030.

66.罗慧敏, 廖湘平, 吴琼. 以肌痛为主要症状的秋水仙碱中毒1例[J]. 中南医学科学杂志, 2021, 49(1): 110-112. [Luo HM, Liao XP, Wu Q. A case of colchicine poisoning with myalgia as the main symptom[J]. Medical Science Journal of Central South China, 2021, 49(1): 110-112.] DOI: 10.15972/j.cnki.43-1509/r.2021.01.022.

67.McEwan T, Bhambra J, Liew DF, et al. Systematic review of colchicine neuro myopathy: risk factors, duration and resolution[J]. Semin Arthritis Rheum, 2023, 58: 152150. DOI: 10.1016/j.semarthrit.2022.152150.

68.Kwon OC, Hong S, Ghang B, et al. Risk of colchicine-associate d myopathy in gout: influence of concomitant use of statin[J]. Am J Med, 2017, 130(5): 583-587. DOI: 10.1016/j.amjmed.2016.12.006.

69.Aghabiklooei A, Zamani N, Hassanian-Moghaddam H, et al. A cute colchicine overdose: report of three cases[J]. Reumatismo, 2014, 65(6): 307-311. DOI: 10.4081/reumatismo.2013.720.

70.石永鹏. 秋水仙碱对小鼠胃肠道微生物及其代谢功能的影响及机制研究[D]. 兰州: 兰州大学, 2024. DOI: 10.27204/d.cnki.glzhu.2023.000027.

71.Hansten PD, Tan MS, Horn JR, et al. Colchicine drug interaction errors and misunde rstandings: recommendations for improved evidence-based management[J]. Drug Saf, 2023, 46(3): 223-242. DOI: 10.1007/s40264-022-01265-1.